Evidence map›Paper›PMID 32533597›Full record

ArticleAddiction (Abingdon, England)2020

Reply to Kunoe (2020) and Ghosh & Singh (2020) regarding Nunes et al. (2020): Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism.

Edward V Nunes, Adam Bisaga, Evgeny Krupitsky, Narinder Nangia, Bernard L Silverman, Sarah C Akerman, Maria A Sullivan

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Addiction (Abingdon, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Sustained-release naltrexone for opioid dependence.The Cochrane database of systematic reviews · 2025
    Pooled it
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Edward V NunesNew York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0002-2055-3425
Adam BisagaNew York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.ORCID 0000-0003-4243-6462
Evgeny KrupitskySt Petersburg Pavlov State Medical University, St Petersburg, Russia.
Narinder NangiaAlkermes, Inc., Waltham, MA, USA.
Bernard L SilvermanAlkermes, Inc., Waltham, MA, USA.
Sarah C AkermanAlkermes, Inc., Waltham, MA, USA.
Maria A SullivanNew York State Psychiatric Institute, Columbia University Irving Medical Center, New York, NY, USA.

Funding

Project-003UG1DA013035 · NIDA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Aimee N Campbell, Jennifer McNeely · 2015 to 2026
$130.3M
Drug Abuse Treatment Development and Research MentoringK24DA022412 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI NUNES, EDWARD V. · 2007 to 2016
$1.7M
NIDA NIH HHS K24 DA022412NIDA NIH HHS UG1 DA013035
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NaltrexoneOpioid-Related DisordersHumansNarcotic AntagonistsNaltrexoneNarcotic AntagonistsCognitionextended-release naltrexonemotivationopioid blockadeopioid dependenceopioid use disorderrelapseretention

Identifiers

PMID32533597
PMCPMC8935659

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.